metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
laNSCLC - M - all population locally advanced NSCLC - maintenance (M) laNSCLC - M - all population
versus placebo
	durvalumab alone
	PACIFIC, 2017 N Engl J Med 2017;377:1919-1929 N. Engl. J. Med. 2018; 379:2342-2350 Lancet Oncol. 2019; 20:1670-1680 Br J Cancer 2020 Dec;123(Suppl 1):18-27. World J Clin Oncol 2020 Nov 24;11(11):898-917. J Thorac Oncol 2021 May;16(5):860-867. Ann Oncol 2020 Jun;31(6):798-806. J Thorac Oncol 2020 Feb;15(2):288-293. J Natl Compr Canc Netw 2021 Feb 2;19(2):153-162. Lung Cancer 2021 Jan;151:30-38. Future Oncol 2021 Apr;17(10):1165-1184. Clin Lung Cancer. 2021 Jun 12;S1525-7304(21)00144-3 ESMO Open 2022; 7:100410-. J Clin Oncol 2022; 40:1301-1311-. NCT02125461	RCT	laNSCLC - M - all population	Durvalumab as consolidation therapy	placebo	patients with stage III unresectable NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy (consolidation therapy)	476 / 237	low	conclusif	demonstrated 32 % decrease in deaths (OS) (PE) demonstrated 48 % decrease in progression or deaths (PFS) (PE) suggested 28 % decrease in deaths (OS) (extension) suggested 45 % decrease in PFS (extension) more...